Roche to invest CHF450m in new diagnostic manufacturing facility in China

Published: 5-Nov-2014
Manufacturing Analysis

To address Asia Pacific’s growing demand for diagnostic tests


Swiss drugmaker Roche will invest CHF450m (US$460m; £294m) over the next three years to establish a new diagnostic manufacturing facility at the Suzhou Industrial Park, in Suzhou, China.

The company aims to address growing demand for diagnostic tests in China and the Asia Pacific region.

As a new addition to Roche’s global diagnostic production network, the Asia manufacturing facility will produce immunochemistry and clinical chemistry tests, which are crucial to clinical laboratory testing.

The facility will focus on packaging operations in the first phase and will be fully operational by 2018, Roche said.

The company plans to build a workforce of more than 600 people at the site over the next several years.

The new site in China will be Roche's eighth worldwide and its first in the Asia Pacific region.

  • Companies:
  • Roche Group
See more

You may also like

Research & Development

Lab standardisation: working smarter to improve patient outcomes

Read more
We’re living in a pivotal time for healthcare, reports Benjamin Lilienfeld, LifeCycle Leader at Roche Diagnostics Solutions. An advanced understanding of diseases, innovative techniques and treatments, a dizzying array of new technologies and a growing population of empowered and knowledgeable patients and caregivers have, together, made healthcare systems increasingly complex

Trending Articles

  1. IMed Consultancy helps Toby Orthopaedics navigate UK regulations Regulatory consultancy ensures compliance and confidence for Miami-based company
  2. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  3. Vetter strengthens senior management team for growth Three new managing directors to support global sustainable development
  4. Samsung Biologics bags $668 manufacturing deal with European pharmaceutical company The CDMO will be responsible for the manufacture of the client's biopharmaceuticals until December 2031
  5. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Research & Development

Lab standardisation: working smarter to improve patient outcomes

We’re living in a pivotal time for healthcare, reports Benjamin Lilienfeld, LifeCycle Leader at Roche Diagnostics Solutions. An advanced understanding of diseases, innovative techniques and treatments, a dizzying array of new technologies and a growing population of empowered and knowledgeable patients and caregivers have, together, made healthcare systems increasingly complex
Ingredients

Horizon Discovery enters into agreement with Roche Diagnostics

Horizon Discovery Group, a specialist in gene editing and gene modulation technologies, announced it has entered into an agreement with Roche Diagnostics to assist in the development of immunohistochemistry (IHC) assays
Distribution

Merck expands distribution agreement with Roche

Merck to be the exclusive supplier of novel enzymes for polymerase chain reaction (PCR) and quantitative real-time PCR, for all countries except the US, Brazil and Japan
Design & Build

Roche to invest CHF3bn over next 10 years at its Basel site

Will build modern research infrastructure, attractive offices and develop a sustainable site
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Reimbursment issues hinder future development of personal therapies

The development of more targeted therapies is moving apace, but are the payers prepared for it? Dr Sarah Houlton looks at the progress of personalised medicines
Manufacturing

2014 ISPE Facility of the Year Awards (FOYA) winners announced

Overall winner will be announced in October in Las Vegas
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Biotech sector regenerates as pharma invests

The rapid pace of development in biologicals and regenerative medicines is changing the landscape of drug manufacture. Big Pharma is keen to join in but future business models look very different. Susan Birks reports
Subscribe now